GEA gets FDA OK for H202 steralisation tech for freeze dryers

- Last updated on GMT

Related tags: Hydrogen peroxide, Food and drug administration, Freeze drying

GEA Lyophil has won US FDA approval for a new gas-based steralistion technology for pharmaceutical freeze drying.

The technology, named Vapovac, uses hydrogen peroxide to sterilse compounds during lyophilisation in place of high pressure steam which is traditionally used.

GEA claim that its approach is safer than steam steralisation, which must be conducted at high temperature and pressure, and is cheaper and faster.

Hubert Kluetsch, Director of Sales and Marketing at GEA Lyophil said that: “Not having the FDA approval has held us back until now as so many potential customers were unable to consider technology that did not have the FDA stamp.

“Now that the FDA has given VAPOVAC its seal of approval, many new markets will be open for us.”

Related news

Show more

Related products

show more

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Follow us

Products

View more

Webinars